Cynthia Latham
LifevantageAbout Cynthia Latham
Independent director (age 67) at LifeVantage since February 2022; tenure ~3.8 years as of Nov 2025 . Background spans 35+ years in direct selling, marketing, and new product development; formerly CMO at Plexus Worldwide and SVP of Marketing at Shaklee, with multiple product patents; BA (Carleton College) and MBA (St. Thomas University) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Latham Consulting Services | President | Feb 2014 – present | Direct selling growth, new product development, strategic market planning |
| Plexus Worldwide | Chief Marketing Officer | Feb 2016 – Apr 2018 | Led rebranding; built R&D/marketing org; drove double-digit revenue growth; CMO of the Year (Phoenix Business Journal, 2017) |
| Shaklee Corporation | SVP Marketing (promoted 2004); prior marketing leadership | May 1996 – Feb 2014 | Led marketing, new product/R&D, branding, market research, sustainability initiatives |
| Quorum International | VP Marketing | Jun 1993 – Apr 1996 | Launched at-home skincare device; created categories generating 40% of business within 6 months |
External Roles
| Organization | Role | Public/Private | Notes |
|---|---|---|---|
| None disclosed | — | — | No other public company directorships disclosed in proxy |
Board Governance
- Independence: Determined independent under Nasdaq rules .
- Committees: Chair, Nominating & Corporate Governance; member, Compensation Committee .
- Board leadership: Independent Chair (Raymond Greer) since Nov 2023; CEO/Chair roles separated .
- Attendance: Board held 6 meetings; each director attended ≥75% of Board and applicable committee meetings. Nominating & Governance met 5 times; Compensation met 9 times .
- Conflicts policy: Directors prohibited from engaging in activities that directly or indirectly compete with LFVN without Board approval .
- Ownership policy: Non-employee directors must hold shares equal to 5x annual base cash compensation; must retain net shares until guideline met .
- Stockholder engagement: Committee chair participated directly in compensation-related outreach after say-on-pay; changes to PRSU mix and metrics followed feedback .
Fixed Compensation
| Component | FY2025 Amount | Details |
|---|---|---|
| Cash fees (retainers) | $69,996 | Monthly retainers: $5,000 for directors; $5,833 for Nominating chair; structure disclosed (amounts shown are actual cash paid) |
| Annual equity grant (restricted stock) | $107,668 (grant-date fair value) | Standard director award equal to $105,000 divided by 10-day average price at election; vests in one installment at one year |
Director compensation structure (reference):
- Chair of Board: $7,000/month; Audit Chair: $6,667/month; Compensation Chair: $6,250/month; Nominating Chair: $5,833/month; Other NEDs: $5,000/month .
Performance Compensation
| Element | Structure | Metrics |
|---|---|---|
| Director equity | Time-based restricted stock | No performance conditions; one-year vesting schedule |
No performance-based metrics are tied to non-employee director pay; PRSU metrics discussed in proxy apply to executives, not directors .
Other Directorships & Interlocks
| Company | Role | Interlock/Conflict |
|---|---|---|
| None disclosed | — | No related-party transactions or interlocks involving Latham disclosed |
Expertise & Qualifications
- Direct selling, marketing, product development; recognized CMO (2017) .
- Product patents; leadership in R&D and branding .
- Board’s skills matrix flags MLM/Direct Selling and Sales/Marketing experience (Latham) .
Equity Ownership
| Item | Value |
|---|---|
| Beneficial ownership (shares) | 51,348 shares (direct) |
| Percent of class | <1% |
| Unvested restricted shares (as of 6/30/25) | 7,819 |
| Options (exercisable/unexercisable) | None disclosed for directors |
| Shares pledged | None disclosed; policy restricts margin/derivatives/short sales |
| Ownership guideline compliance | Meets 5x base cash guideline based on 51,348 shares and $10.68 share price at record date (indicative value ≈ $548k vs guideline of $300k) |
Insider Trades
| Period | Form 4 Activity | Section 16(a) Delinquencies |
|---|---|---|
| FY2025 | Not disclosed in proxy | No delinquent filings reported for Latham in FY2025; delinquencies noted for other insiders only |
Governance Assessment
- Positive signals:
- Independent director; chairs Nominating & Governance (key governance oversight) and serves on Compensation Committee .
- Attendance at or above policy threshold; active committee cadence (Nominating 5; Compensation 9 meetings) indicates engagement .
- Strong ownership alignment and compliance with 5x guideline; equity grant vests after one year; hedging/shorting prohibited .
- No related-party transactions or Section 16(a) issues disclosed for Latham .
- Watch items:
- Consulting business in direct selling sector could present perceived conflicts if clients overlap with LFVN competitors; Board conflicts policy requires notice/approval for competitive activities (no issues disclosed) .
- Board under Cooperation Agreement with activist holders through FY2027 window—ongoing refresh dynamics; not specific to Latham but relevant to board stability .
No RED FLAGS identified for Latham (no pledging, no related-party transactions, no filing delinquencies) based on disclosed materials .